Breaking Down the Pink Pill Controversy

Men have had over two dozen pills designed to treat sexual dysfunction.

• Pink Viagra products sometimes come with misleading advertising claims.
• They often promise instant or dramatic sexual performance improvements.
• Many pink Viagra supplements have no clinical testing or approval.
• The trade name "Pink Viagra" is not an official pharmaceutical name.
• There are risks associated with counterfeit or substandard pink Viagra pills.
• Some users experience allergic reactions to unknown ingredients.
• The market for pink Viagra is flooded with low-quality or harmful products.
• Regulatory agencies detect and shut down illegal pink Viagra sales.
• Public awareness campaigns target unregulated sexual enhancement supplements.

The drug is nicknamed Addyi and and it's the first to treat women with low or no desire.

The nurses at Stanford's Gynecology Clinic have been busy fielding calls from patients wanting to know about what some are calling female Viagra.

May 27: Deadly chemical tank disaster, Cave rescue

In addition, the FDA is requiring the company that owns Addyi to conduct three well-designed studies in women to better understand the known serious risks of the interaction between Addyi and alcohol. Addyi is a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, but the mechanism by which the drug improves sexual desire and related distress is not known. It is dosed at bedtime to help decrease the risk of adverse events occurring due to possible hypotension, syncope and central nervous system depression (such as sleepiness and sedation). Patients should discontinue treatment after eight weeks if they do not report an improvement in sexual desire and associated distress. Is the new little pink pill made to improve sexual desire in some women the latest accessory to the little black dress?

Related support groups

It comes with warnings of serious side effects, experts said. The federal Food and Drug Administration approved Addyi August 2015. Being called the “female Viagra,” it’s the first medication to increase sexual desire in some pre-menopausal women. But take note: it works much differently than its male counterpart, Viagra, said Sara Griesbach, Marshfield Clinic director of clinical pharmacy services. Addyi, or flibanserin, works by stimulating certain receptors in the brain and blocking others.

Daddy Yankee: A Higher Note

How it works to increase sexual desire is not completely understood, Griesbach said. The drug increased the number of satisfying sexual events by about 0.5 to one additional event per month in women who participated in clinical trials. Women must take the pill daily to improve female sexual desire, and it could take up to a month to notice results. Viagra, on the other hand, is taken shortly before sexual activity and treats erectile dysfunction in men by increasing blood flow so an erection can occur. “This medicine is approved by the FDA, but there are a lot of safety concerns people need to be aware of,” Griesbach said. The little pink pill called Flibanserin is geared toward premenopausal women who have low libido.

"This will be a historic moment for women," Leah Millheiser, M.D., said. Millheiser says one in 10 women suffer from what's known as hypoactive sexual desire disorder. She's a Stanford doctor who conducted landmark research in 2009, which found the brains of women with the disorder are different.

What women are saying

"And to lump every individual into this group as potentially being amenable to drug therapy seems ill-advised." Some call it "female Viagra", a little pink pill meant to help some women awaken their sex drive. Health reporter Erin Billups takes a look at the medication and what it may mean for the future and filed the following report. Sexual dysfunction is a favorite topic of comedians, but for most women dealing with sexual desire disorders it's no laughing matter. For the first time, there is a new drug on the market for these women - Flibanserin - from Valeant Pharmaceuticals. "This is for the patient who has all the, what we call the right kind of formula for being in a healthy sexual relationship and just doesn’t want to have sex and is bothered by that," explains Dr.

Los Angeles Times: As FDA Approves 'Pink Viagra' For Women, Controversy Persists

Elizabeth Kavaler, a urologist at Lenox Hill Hospital. Some have dubbed it the "female Viagra" but it works differently than the little blue pill. "Flibanserin is a medication that works on the brain, on the neurotransmitters of the brain. And it modulates the serotonin and the dopamine levels in the brain so that there is a sense of good feeling," says Kavaler. It's approved for women 50 or younger, but most experts like Kavaler agree, female sexuality and desire is complex and in most cases can't be fixed outright with a pill.

Freight train derailment in Posen, IL

Which is why the treatment is seen as controversial. "The idea that you’re going to give a woman a drug so she wants to have sex with you is disturbing to a lot of women," Kavaler points out. Medical ethicist Arthur Kaplan says it's just the latest trend in pharmaceutical innovation - medication that affects the brain. "We have pills that are obviously starting to do that. That's what a lot of the things that are calming you down do and I think we'll see more of that. She believes the new drug the FDA approved effectively targets the chemical imbalance. "Look the data speaks for itself, people doubled the amount of sexually satisfying events who were on the drug in the study," Millheiser said.

See also:

Addyi can cause low blood pressure and fainting, so it should be taken at bedtime. Drinking alcohol increases the risk of side effects. “If there’s any chance the patient will use alcohol, this medicine is not for them,” she said. Nursing mothers and patients with liver problems shouldn’t use Addyi, and it interacts with a number of other medicines, including birth control pills. Ongoing studies will evaluate the long-term effects and safety viagra sildenafil price of Addyi.

Building A.I.: The Deep Mind Behind the Moment

If you’re interested in Addyi, ask your doctor if it’s an option for you. Discuss whether the benefits are worth the risks, Griesbach said. “The important point with hypoactive sexual desire is that non-medicine options should be considered first,” she said. She suggested lifestyle modifications, such as reducing stress and fatigue, increasing quality time with your partner and improving body image before using medicine to improve sexual desire. Your doctor also should rule out medical causes of low sexual desire. The FDA advisory panel heard from women who want the pill and also received a letter of opposition signed by several health care advocacy groups, including San Francisco's Breast Cancer Action. "We're concerned that drug companies are trying to sell hope and hype," Breast Cancer Member Karuna Jaggar said.

1 thought on “Love, Sex, and Pink Viagra”

Addyi is anticipated to hit the market this fall, and a team of Marshfield Clinic pharmacists and doctors from across the system are evaluating the drug. “We review the effectiveness and safety of new medicines and assess where the medicine fits in the overall care of our patients,” Griesbach said. “We definitely plan on reviewing this medicine in the near future.” Doctors and pharmacists must undergo training before prescribing and dispensing the drug. It’s not yet known how much Addyi will cost or whether it will be covered by health insurance. Addyi, the first medication to treat low sex drive in women, already has a nickname: "Pink Viagra." Last week, the FDA approved the medication for treatment of Hypoactive Sexual Desire Disorder where patients' lack of sexual desire causes them personal distress. Jaggar says the data doesn't show the benefit outweighs the potential harm of the little pink pill.

"This is a drug that you take every day, that stays in your blood stream, reduces blood pressure, increases the risk of fainting and interacts with common drugs such as alcohol, birth control and other pills," she said.

ABC News Live Presents

It has its own risk, you're mucking around in the brain, you're changing the chemistry like sex. Obviously we could try for this with appetite in obesity and things like that," says Caplan. Little more than a third of women in clinical trials saw an increase in sexual desire. Still, Kavaler says it's better than nothing. "It’s refreshing that we can have these conversations and that women can start to talk about their sexuality and their concerns.

Leaders of top AI companies divided on job market impact

Even if they are not necessarily candidate for this medication," she says. Flibanserin is approved for use for those diagnosed with hypoactive sexual desire disorder (HSDD) or inhibited sexual desire (ISD) is considered a sexual dysfunction and is characterized as a lack or absence of sexual fantasies and desire for sexual activity. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. HSDD is acquired when it develops in a patient who previously had no problems with sexual desire. HSDD is generalized when it occurs regardless of the type of sexual activity, the situation or the sexual partner.

NYC Mayor Mamdani makes housing announcement

Addyi (Flibanserin) can cause severely low blood pressure (hypotension) and loss of consciousness (syncope). These risks are increased and more severe when patients drink alcohol or take Addyi with certain medicines (known as moderate or strong CYP3A4 inhibitors) that interfere with the breakdown of Addyi in the body. Because of the alcohol interaction, the use of alcohol is contraindicated while taking Addyi. Health care professionals must assess the likelihood of the patient reliably abstaining from alcohol before prescribing Addyi. Addyi is also being approved with a Boxed Warning to highlight the risks of severe hypotension and syncope in patients who drink alcohol during treatment with Addyi, in those who also use moderate or strong CYP3A4 inhibitors, and in those who viagra 100mg have liver impairment. The drug will carry a warning label and will not be advertised on radio or television for the next 18 months.

Schlossberg addresses absence of Mamdani's endorsement

A few days after approval, Sprout Pharmaceuticals -- the company that makes Addyi -- was bought for a $1 billion. Dr. Alan Altman, of Aspen, was among those who worked to get the drug approved by the Food and Drug Administration. Altman specializes in treating sexual dysfunctions and is on Sprout Pharmaceuticals' board. SAN FRANCISCO (KGO) -- The Federal Drug Administration Tuesday approved the first prescription drug to boost sexual desire in women, a milestone long sought by the pharmaceutical industry. The new drug's label will carry a bold warning that combining it with alcohol can cause dangerously low blood pressure and fainting.

• Pink Viagra is linked to the broader category of sexual wellness products.
• It competes with herbal supplements and other natural remedies.
• The market is driven by increasing awareness of sexual health.
• Consumers are advised to choose products with regulatory approval.
• Unscrupulous vendors often exploit demand with false claims.
• Regular medical check-ups are recommended for ongoing sexual issues.
• Personalized treatment plans are more effective than over-the-counter products.
• Comprehensive sexual health education reduces reliance on unverified solutions.
• Research continues into safe and effective sexual enhancement options.

Those problems can also occur if the drug is taken alongside certain common medications, including drugs used to treat yeast infections.